These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 36140182)

  • 1. The Features of Checkpoint Receptor-Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition.
    Kuzevanova A; Apanovich N; Mansorunov D; Korotaeva A; Karpukhin A
    Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Progress on tumor immune checkpoints and their inhibitors in tumor therapy].
    Wang L; Bai L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jul; 37(7):663-670. PubMed ID: 34140079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
    Kreidieh FY; Tawbi HA
    Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
    Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
    ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Insights Into Novel Immune Checkpoint Inhibitors.
    Lee JB; Ha SJ; Kim HR
    Front Pharmacol; 2021; 12():681320. PubMed ID: 34025438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future.
    Pan M; Zhao H; Jin R; Leung PSC; Shuai Z
    Front Immunol; 2023; 14():1156212. PubMed ID: 37090741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach.
    Kgatle MM; Boshomane TMG; Lawal IO; Mokoala KMG; Mokgoro NP; Lourens N; Kairemo K; Zeevaart JR; Vorster M; Sathekge MM
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
    Cai L; Li Y; Tan J; Xu L; Li Y
    J Hematol Oncol; 2023 Sep; 16(1):101. PubMed ID: 37670328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands.
    Kamali AN; Bautista JM; Eisenhut M; Hamedifar H
    Ther Adv Vaccines Immunother; 2023; 11():25151355231192043. PubMed ID: 37662491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.
    Luo Y; Yang YC; Shen CK; Ma B; Xu WB; Wang QF; Zhang Y; Liao T; Wei WJ; Wang Y
    Front Endocrinol (Lausanne); 2022; 13():859013. PubMed ID: 35574031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.
    Torphy RJ; Schulick RD; Zhu Y
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29211042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors.
    Catalano M; Shabani S; Venturini J; Ottanelli C; Voltolini L; Roviello G
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.
    Yeo J; Ko M; Lee DH; Park Y; Jin HS
    Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33670993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint targeting TIGIT in hepatocellular carcinoma.
    Zheng Q; Xu J; Gu X; Wu F; Deng J; Cai X; Wang G; Li G; Chen Z
    Am J Transl Res; 2020; 12(7):3212-3224. PubMed ID: 32774695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint expression patterns on T cell subsets in light-chain amyloidosis: VISTA, PD-1, and TIGIT as potential therapeutic targets.
    Wang J; Zhao Y; Liao P; Huang S; Huang Y; Chen S; Li Y; Zhong L
    Blood Sci; 2024 Jan; 6(1):e00181. PubMed ID: 38226018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Targets of Immunotherapy in Gynecologic Cancer.
    Cheng H; Zong L; Kong Y; Gu Y; Yang J; Xiang Y
    Onco Targets Ther; 2020; 13():11869-11882. PubMed ID: 33239889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.
    Chiang EY; Mellman I
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.